Publication
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (10)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 10
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugCapivasertibcivic_curation1.00
- drugFulvestrantcivic_curation1.00
- geneAKT1civic_curation1.00
- genePIK3CAcivic_curation1.00
- genePTENcivic_curation1.00
- variantAKT1 Mutationcivic_curation1.00
- variantPIK3CA Mutationcivic_curation1.00
- variantPIK3CA R88Qcivic_curation1.00
- variantPTEN Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (20)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 37256976
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| AKT1 Mutation + PIK3CA Mutation + PTEN MutationPIK3CAPTENAKT11 | ||||||||
| Capivasertib + FulvestrantCombination | Malignant Breast Neoplasm | Predictive | A | Supports Sensitivity Response | 3 | accepted | EID12020In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC | civic |
| AKT1 E17K1 | ||||||||
| Capivasertib + FulvestrantCombination | HER2 Negative Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 3 | submitted | EID12181In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC | civic |
| PIK3CA C420R1 | ||||||||
| Capivasertib + FulvestrantCombination | HER2 Negative Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12183In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC | civic |
| PIK3CA E542K1 | ||||||||
| Capivasertib + FulvestrantCombination | HER2 Negative Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12184In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC | civic |
| PIK3CA E545A1 | ||||||||
| Capivasertib + FulvestrantCombination | HER2 Negative Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12185In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC | civic |
| PIK3CA E545D1 | ||||||||
| Capivasertib + FulvestrantCombination | HER2 Negative Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12186In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC | civic |
| PIK3CA E545G1 | ||||||||
| Capivasertib + FulvestrantCombination | HER2 Negative Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12189In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC | civic |
| PIK3CA E545K1 | ||||||||
| Capivasertib + FulvestrantCombination | HER2 Negative Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12188In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC | civic |
| PIK3CA E545Q1 | ||||||||
| Capivasertib + FulvestrantCombination | HER2 Negative Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12187In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC | civic |
| PIK3CA G1049R1 | ||||||||
| Capivasertib + FulvestrantCombination | HER2 Negative Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12198In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC | civic |
| PIK3CA H1047L1 | ||||||||
| Capivasertib + FulvestrantCombination | HER2 Negative Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12197In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC | civic |
| PIK3CA H1047R1 | ||||||||
| Capivasertib + FulvestrantCombination | HER2 Negative Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12196In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC | civic |
| PIK3CA H1047Y1 | ||||||||
| Capivasertib + FulvestrantCombination | HER2 Negative Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12195In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC | civic |
| PIK3CA M1043I1 | ||||||||
| Capivasertib + FulvestrantCombination | HER2 Negative Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12194In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC | civic |
| PIK3CA M1043V1 | ||||||||
| Capivasertib + FulvestrantCombination | HER2 Negative Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12193In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC | civic |
| PIK3CA N345K1 | ||||||||
| Capivasertib + FulvestrantCombination | HER2 Negative Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 3 | submitted | EID12182In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC | civic |
| PIK3CA Q546E1 | ||||||||
| Capivasertib + FulvestrantCombination | HER2 Negative Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12190In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC | civic |
| PIK3CA Q546K1 | ||||||||
| Capivasertib + FulvestrantCombination | HER2 Negative Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12191In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC | civic |
| PIK3CA Q546P1 | ||||||||
| Capivasertib + FulvestrantCombination | HER2 Negative Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12192In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC | civic |
| PIK3CA R88Q1 | ||||||||
| Capivasertib + FulvestrantCombination | HER2 Negative Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 2 | accepted | EID12034In this phase 3 double-blind trial, the efficacy of capivasertib and fulvestrant combination therapy was tested in 708 patients with HR+/HER2- breast cancer. Among these 708 patients, 40.8% (n = 289) … (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC | civic |